Loading…
* Free cash flow = OCF − net investing outflow (the filings carry no standalone capex line).
Dividends declared (per SOCE filings): FY2022 0 · FY2023 5,024 · FY2024 7,803 — 3-yr total 12,827
Aversi-Pharma is Georgia's leading pharmacy chain, founded 1994 as a family-run pharmaceutical distributor. Operates 332 stores and the largest pharmaceutical factory in Georgia, employs 10,000+ people, and since 2007 runs Aversi Clinic — a multi-profile medical-diagnostic chain across the Caucasus.
Group parent — controls 4 companies · ownership
| Line item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | CAGR |
|---|---|---|---|---|---|---|---|---|---|
| 198,805 | 210,261 | 207 | 242,114 | 299,795 | 327,674 | 358,069 | 399,099 | +10.5% | |
| 169,827 | 191,837 | 457,502 | 253,399 | 271,670 | 305,931 | 350,792 | 411,105 | +13.5% | |
| TOTAL ASSETS | 368,632 | 402,098 | 457,709 | 495,513 | 571,465 | 633,605 | 708,861 | 810,204 | +11.9% |
| 123,542 | 124,623 | 137 | 154,061 | 167,614 | 179,178 | 210,057 | 224,988 | +8.9% | |
| 46,750 | 51,763 | 216,524 | 74,198 | 59,248 | 48,476 | 44,676 | 75,707 | +7.1% | |
| TOTAL LIABILITIES | 170,292 | 176,386 | 216,661 | 228,259 | 226,862 | 227,654 | 254,733 | 300,695 | +8.5% |
| 198,340 | 225,712 | 241,048 | 267,254 | 344,603 | 405,951 | 454,128 | 509,509 | +14.4% | |
| Balance Check (Assets - L&E) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Debt analysis | |||||||||
| Total Debt | 60,864 | 66,769 | 106,188 | 100,748 | 82,814 | 66,600 | 66,628 | 83,230 | +4.6% |
| Cash & Equivalents | 21,056 | 26,244 | 11,755 | 15,028 | 9,785 | 32,377 | 39,423 | 32,124 | +6.2% |
| Net Debt | 39,808 | 40,525 | 94,433 | 85,720 | 73,029 | 34,223 | 27,205 | 51,106 | +3.6% |
Shareholders, directors and group links from the companyinfo.ge public register — as filed, so stakes need not sum to 100% where a holding is undisclosed.
Ownership & directors from companyinfo.ge (public corporate registry).
Ranked by how close each latest revenue is to this one — not a curated comp set. Open this set in Compare →